Advocacy Partner: Muscular Dystrophy Association
About the Muscular Dystrophy Association
MDA has been at the center of progress for people living with muscular dystrophy, ALS, and over 300 other neuromuscular conditions for over 75 years. We unite researchers, clinicians, advocates, and families to speed the pace of discovery, improve access to expert care, and ensure inclusion in every aspect of life. Our mission is simple: give the people we serve the tools and opportunities to live longer, more independent lives.
For support, guidance, and resources please visit: MDA Resource Center
By Phone: 1-833-ASK-MDA1 (1-833-275-6321)
By Email: [email protected]
Resources
MDA Resource Center
MDA’s Resource Center is a hub for questions and assistance for all things MDA, support, events, and more.
Durable Medical Equipment (DME) Grant Program
MDA is proud to offer the Durable Medical Equipment (DME) Grant to help children and adults living with neuromuscular diseases get the equipment they need to live more independently and comfortably. We know how expensive and hard it can be to access the right equipment. This program helps reduce the cost of items like mobility aids, lift chairs, and more, giving families extra support and peace of mind.
MDA Gene Therapy Support Network
MDA has invested over $125M in the development of gene therapy (GTx) for neuromuscular diseases over the past 20 years. With new gene therapy drug approvals in the pipeline, MDA is here to facilitate access and to provide support and education to the neuromuscular disease community.
MDA Community Education
MDA’s Community Education programs aim to support every person and family living wtih neuromuscular disease through the delivery of relevant, responsive, and actionable content from leading experts in the field. These programs focus on navigating critical life transitions, increasing disease understanding, and supporting access to independence.
MDA Summer Camp
At MDA Summer Camp, every camper finds a place to belong in a community rooted in inclusion, friendship, and fun. Here, kids and young adults with neuromuscular disease grow in confidence as they take on new adventures, make lifelong friends, learn to self-advocate, and discover just how much they can do.
Upcoming events
2026 Puerto Rico Muscle Walk
2027 MDA Clinical and Scientific Conference
About Advocacy Partners
The information above is provided by our partner. Learn more about our advocacy partners here.
Muscular Dystrophy Association News
Discussion
Drug maker Servier announced that it is discontinuing development of its oral treatment candidate sevasemten for both Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). The announcement comes just days after top-line data, or the first results of a clinical trial, showed that sevasemten had…
Discussion
Sarepta Therapeutics will not reopen enrollment in a global clinical trial testing its gene therapy Elevidys (delandistrogene moxeparvovec-rokl) in boys and men with Duchenne muscular dystrophy (DMD), the company announced in a community letter. The Phase 3 trial, called ENVISION (NCT05881408), was designed to assess Elevidys’…
Discussion
The recent Muscular Dystrophy Association (MDA) Engage Community Seminar with Stanford Medicine was packed with educational sessions, but some of the most meaningful takeaways for participants were about connection and community. “That’s what makes MDA Engage Symposium so special,” Marissa Lozano, director of community education at the MDA,…
Discussion
Using a computer-based approach, researchers in China have created an online tool, dubbed DMD-TIMER, to predict when children with Duchenne muscular dystrophy (DMD) are likely to lose the ability to walk. The new tool, which uses clinical and MRI assessments, was developed using machine learning, a type of…
Discussion
A large clinical trial evaluating the treatment candidate sevasemten for people with Becker muscular dystrophy (BMD) has failed to meet its main goal, with “no statistically significant benefit” seen on a measure of physical function. That’s according to top-line data, or the first study results, from GRAND…
Discussion
Treatment with the experimental gene therapy BB-301 was found to improve swallowing ability for every person with a rare type of muscular dystrophy (MD) that mainly affects the throat and eyes who are taking part in a first-in-human clinical trial. That’s according to new interim data announced by Benitec…
Recent Posts
- MDA Engage: California event highlights community connection
- MDA applauds new US federal court decision on Medicaid coverage
- MDA Engage: Event sessions highlight community, hope
- MDA Engage: National ambassador brings message of belonging, resilience
- MDA Engage: ‘I am not alone’ was the biggest takeaway in Chicago
